The Advisory committee meeting will be the driver for this stock
a bit from the recent Bell Potter report
"Since issuing the DSC in January the FDA has continued to consider new product
approvals in TRT. This includes a new oral formulation and a nasal drop formulation.
While this neither proves nor disproves any safety concerns, it is not unreasonable to
conclude that if the FDA had genuine safety concerns, surely all new product
approvals would have been suspended.
The Advisory Committee is likely to make a recommendation to the FDA or adopt
another course of action. Based on the overwhelming evidence from previous clinical
trials in long term use of TRT, we are confident it will have an ongoing position in the
market for men’s health. For this reason we expect the market will resume growth in
calendar 2015 and quickly recover the estimated 25% of lost volume that has occurred
in 2014."
Let's hope for the longs they're correct.
Add to My Watchlist
What is My Watchlist?
